Call for Abstract

6th International Conference and Exhibition on Cell and Gene Therapy, will be organized around the theme “Exploring the novel research and innovations in Cell & gene therapy”

Cell Therapy 2017 is comprised of 24 tracks and 34 sessions designed to offer comprehensive sessions that address current issues in Cell Therapy 2017.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

Cell therapy market investigation gives information about generally accepted clinical and analytical methods that are currently in use for applying cell therapy techniques. It is mainly used mainly in clinics and hospitals. Analysis is done on those companies and products that are actively developing and marketing instrumentation, reagents, and supplies for cell therapy. The cell-based research markets was analysed for 2015, and projected to 2025.They analysed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.

Cell therapy technologies overlap with those of gene therapy,immune therapy cancer vaccines, drug delivery, drug discovery, tissue engineering and regenerative medicine. The cellular therapy technologies and methods, which have already started to play a very important role in the practice of medicine. Cell treatments and immunotherapies are changing the substance of pharmaceutical, empowering specialists, doctors and researchers to address the side effects of a sickness, as well as its basic causes, basically educating the body to recuperate itself. The pace of current advancements in cell treatment and immunotherapy is promising, with a few scientists reporting remarkable clinical results.

Cardiovascular disease implies a range of disease entities whose therapeutic actions differ. Cell therapy is a 21st century approach which is used to treating the cardiovascular disease and now it is being applied worldwide. However, no concerted approach exists for defining the best treatment conditions.Cardio vascular disorders  remains the number one cause of morbidity and mortality in the United States and Europe. In the United States alone, ≈1 million patients are suffering with myocardial infarction every year, with an associated mortality of 26% at 3 years.

A number of cell and gene therapy strategies are being evaluated in patients suffering from cancer and these include manipulating cells to gain or lose function. Clinical trials of cell therapy for many different cancers are currently ongoing.  The scientists has recently  developed novel cancer therapies by combining both gene and cell therapies. Cancer therapeutics cannot cure cancer and yet in 2014, the overall market for Oncologic therapeutics stood at about $84.3 billion. Any drug that can treat a reasonable survival of more than five years for cancer patients can achieve a blockbuster status. Within oncologic therapeutics, immunotherapeutic drugs have increased worldwide acceptance, because they are targeted drugs targeting only cancer cells.

  • Track 4-1Breast cancer therapy
  • Track 4-2Lung cancer therapy
  • Track 4-3Prostate cancer therapy
  • Track 4-4Modern approaches in molecular cancer therapeutics
  • Track 4-5Challenges & risks of cancer therapy

New visions into the biology of neural stem cells (NSCs) have raised expectations for their use in the treatment of neurologic diseases. The truth is that the field is moving forward every year, well thought out clinical trials are being planned and undertaken, but to date none have shown  a level of effectiveness that gives hope they may be useful as mainline therapies in 2013. With period, development will be made, but it is only by following the well-established methods of transformation from the laboratory to the clinic that this can happen. If such approaches are abandoned in the rush to get to clinic, then there is a real risk that the whole field will be derailed by a terrible result of an ill thought out treatment. If this were to happen then those treatments being advanced using sound scientific principles and which promise to be of a great use in the future, will instead be lost forever as the unproven, commercially driven cells of today confuse and kill the field. Cell therapy and gene transfer to the diseased or injured brain have provided the basis for the development of potentially powerful new therapeutic strategies for a broad spectrum of human neurological diseases.

Stem cell technology is the subject of much discussion and interest across the world. Newspapers and websites frequently report new discoveries, and this fast-paced field has been the focus of hope, excitement and sometimes controversy. Policy makers, regulators, researchers,clinicians and scientists are constantly debating the progress and potential applications of this exciting science. This Stem cell global  strategic report will help us to understand unique product opportunities by stem cell type, derive more revenue from products sold to stem cell scientists, and identify new product growth opportunities before the competition. Use the Survey of Stem Cell Scientists & researchers to understand technical requirements, unmet needs, and purchasing preferences of stem cell researchers worldwide.

  • Track 6-1Adipose derived stem cells
  • Track 6-2Hair follicle cells
  • Track 6-3Blood stem cells
  • Track 6-4Skin grafting
  • Track 6-5Human somatic cells

Getting cell therapy products onto the market as quickly as possible still remains a key driver in the improve of recombinant therapeutic proteins. Any such advance in bioprocessing is of particular interest to the industry if it considerably shortens the development timeline or improves the end product. In the monoclonal antibody (MAb) area, platform procedures have allowed companies to regulate on particular mammalian cell lines, transfection approaches, process conditions and also downstream processing to shorten the development timeline.

The global cell line growth development in the market is segmented on the basis of products, types of cell lines used, the source of cell lines, applications, and geographies. The global cell line development market size was valued at USD 2.38 billion in 2014. The key growth drivers include the increasing demand for monoclonal antibodies, raising demand for effective cancer treatments and technical advancements introduced in this field. The global cell line growth market size was valued at USD 2.38 billion in 2014. Key growth drivers include the rising demand for monoclonal antibodies, raising demand for effective cancer therapeutics and technical advancements introduced in this field.

The Global Tissue Science & Regenerative Medicine Market is estimated to observe the highest development coming from the Tissue Engineering segment. By technology type, biomaterial segment presently holds the largest market share of global regenerative medicine market. However, Tissue Engineering segment is expected to be the fastest growing segment over the forecast period. In terms of value, the tissue engineering segment market is anticipated to increase at an outstanding CAGR of 17.5% over the forecast period of 2015-2019, to reach a market value of about US$ 1,070 Mn by 2019. Currently, it accounts for almost 13.2% of the total share of the global regenerative medicine market, which is expected to increase growth potentially by 2019 end.

Currently, the concept of gene therapy is being authorized by numerous pharmaceutical companies using clinical data, and there is a increasing interest among venture capitalists to discover the commercial potential of gene therapy. However, the development of the gene therapy market is largely needy on the regulatory environment, and on approvals from industry bodies. Currently, most gene therapy products are still in the clinical trials phase II and phase III, of which a common focuses on the treatment of oncology and heart diseases. The growing popularity of DNA vaccines has positively impacted the development of this market, and there is a high chance of cell and gene therapy being practiced in clinics in the next few years, as encouraging results are developing from the phase II/III trials. Gene therapies market will generate $204m in 2020, according to new visiongain analysise 2 diabetics. 

Initially, scientists followed gene therapy for the administration of genetic material to treat genetic disorders, and it was soon adapted for cancer treatment. Approximately two-thirds of the clinical trials in gene therapy have been designed at the treatment of various types of cancers.  Cancer Gene Therapy Market size was USD 805.5 million in 2015, with 20.7% CAGR estimation from 2016 to 2024; as per a new global strategic research report. Globally, increasing cancer prevalence will rise demand for gene therapy as the effective personalized treatment choice.  According to WHO, cancer incidence is estimated to rise by 50% to reach 15 million by the end of this decade. This  increase in number of patients needs this as a potential treatment approach addressing the growing global burden of the disease.

Recent developments in the field of molecular and cell biology may allow for the growth of novel strategies for the therapy and cure of type 1 diabetes. In particular, it is now possible to predict restoration of insulin secretion by gene or cell-replacement therapy. Diabetes mellitus is growing globally affecting more than 180 million people worldwide . This is mostly type 2 diabetes and, because of the growth in the aging population and massive increase in prevalence of obesity, the incidence is likely to be more than doubled by 2030.

According to the new research Global  strategic report Gene Therapy Market Forecast to 2020, a major focus has been on the on-going clinical trials for the growth of innovative products using different vectors. Increasing number of clinical trials and availability of wide range of genes and vectors used in these trials will enable emergence of new therapy modalities to help make cancer a manageable disease. By the end of 2012, the expected number of clinical trials crossed 1,800 worldwide.

The global Epigenetic strategic research market was valued at an estimated $413.24 Million in 2014. This market is expected to ncrease at a CAGR of 13.64% between 2014 and 2019 to reach $783.17 Million in 2019. This Market is segmented mainly on the basis of products into enzymes; instruments and consumables; kits; and reagents. Each of these market is further divided into multiple product segments and sub-segments.

  • Track 14-1Single gene inheritance/ monogenetic disorders
  • Track 14-2Multifactorial inheritance
  • Track 14-3Chromosome abnormalities

The National Human Genome Research Institute describes genomic medicine as "an developing medical discipline that mainly involves using genomic information about an individual as part of their clinical care (e.g., for diagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use. Geographically, the global Genomic Medicine market is classified into different regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan, Middle East and Africa (MEA). Owing to the presence of huge number of academic as well as research institutions in the United States. which are mainly working on genomic medicine to discover next-generation genomic medicines, North America region is expected to lead the global genomic market in terms of value during the forecast period. Also, the presence of several academies offering educational programs coupled with openings in scientific research  in the North America and Europe is expected to have positive impact on the regional markets. The genetic & genomic medicine concept still in its nascent stage is yet to receive an drive from the emerging market which are anticipated to hold smaller shares in the global market.

  • Track 15-1Human Genetics
  • Track 15-2Genetic Counselling
  • Track 15-3Pharmacogenetics

The major theme of this  is whether gene therapy can attain commercial success by the early-to-mid 2020s, which types of gene therapy programs have the greatest likelihood of success, and what hurdles might stand in the way of clinical and commercial success of leading gene therapy programs. Asynchrony between the maturation of gene therapy technologies and capital investment in development-focused business models may have stalled the commercialization of gene therapy.

  • Track 16-1Stem cell applications in cosmetics longevity
  • Track 16-2Plant extracts & commercial uses
  • Track 16-3New era in plant stem cell technology

Gene therapy is a logical way to treat rare genetic disorders; and cure a single gene defect by introducing with a 'correct' gene. The first gene-therapy trials were conducted using patients with rare monogenetic disorders, but these are now outstripped by the clinical testing of gene therapeutics for more common conditions, for ex: cancer, AIDS and heart disease. This is partially due to a failure to achieve long-term gene expression with early vector systems, a critical condition for correcting many inborn genetic defects. 

clinical trial is a research study that seeks to determine if a treatment is safe and effective. Advancing new cell and gene therapies (CGTs) from the laboratory into early-phase clinical trials has proven to be a complex task even for experienced investigators. Due to the wide variety of CGT products and their potential applications, a case-by-case assessment is warranted for the design of each clinical trial.

Objectives: Determine the pharmacokinetics of this regimen by the persistence of modified T cells in the blood of these patients, Evaluate the immunogenicity of murine sequences in chimeric anti-CEA Ig TCR, Assess immunologic parameters which correlate with the efficacy of this regimen in these patients, Evaluate, in a preliminary manner, the efficacy of this regimen in patients with CEA bearing tumours.

The genome editing market is expected to reach USD 5.54 billion by 2021 from USD 2.84 Billion in 2016, and it wil grow  at a CAGR of 14.3% in the next five years (2016 to 2021). The growth of the overall market can be accredited to factors such as increasing government funding and growth in the number of genomics projects, high prevalence rate of infectious diseases and cancer among patients, technological advancements, increasing demand for synthetic genes, growing awareness about genomics, and increasing new product launches by industry players are expected to drive the market in the coming years. Rise in the production of genetically modified crops is also expected to increase the demand for genome editing.

  • Track 19-1Tumor suppressor genes
  • Track 19-2Bio markers involved in gene therapy
  • Track 19-3Genetic screening and diagnostics
  • Track 19-4Cloning & expression systems
  • Track 19-5Mobile genetic elements
  • Track 19-6Vectors of gene therapy
  • Track 19-7Cellular & organismal genetic engineering
  • Track 19-8Gene transfer to induce cellular programming
  • Track 19-9Therapies for genetic disorders/ autoimmune diseases

The Center for Biologics Evaluation and Research (CBER) controls cellular and gene therapy products and certain devices related to cell and gene therapy.  In addition to regulatory oversight of clinical studies, it also provides proactive scientific and supervisory advice to medical and clinical researchers and manufacturers in the area of novel product development.

The use of human embryos for research on embryonic stem (ES) cells is currently top on the ethical and political agenda in many countries. Notwithstanding the potential benefit of using human Embryonic Stem cells in the treatment of diseases, their use remains controversial because of their origin from early embryos.

Cell therapy  products require a variety of safety considerations. Stem cell and gene  products are heterogeneous substances. There are several areas that particularly need to be addressed as it is quite different from that of pharmaceuticals. These range from creating batch consistency, product stability to product safety, strength  and efficacy through pre-clinical, clinical studies and marketing authorization. This review summarizes the existing regulations/guidelines in US, EU, India, and the associated challenges in developing SCBP with emphasis on clinical aspect.

Recent clinical trials of gene and cell therapy have shown remarkable therapeutically benefits and an excellent safety record. They provide evidence for the long-sought promise of gene and therapy to deliver 'cures' for some otherwise terminal disabling conditions. Behind these advances lie enhanced vector designs that enable the safe delivery of therapeutic genes to particular cells. Technologies for editing genes and modifying inherited mutations, the meeting of stem cells to regenerate tissues and the effective exploitation of powerful immune responses to fight against cancer are also contributing to the regeneration of gene therapy.

The number of companies involved in cell therapy has improved remarkably during the past10 years. More than 550 companies have been identified and they particularly work on cell therapy. Of these companies, 170 are involved in stem cells. Profiles of 72 academic institutions paticularly in the US involved in cell and gene  therapy.